Improving Care for People with VWD | May 18 2021- Arabic

Listen to this 90-minute webinar presented on May 18, 2021 to learn about the recently published ASH ISTH NHF WFH 2021 Guidelines on the Diagnosis and Management of von Willebrand Disease (VWD). The session was moderated by Nathan Connell (Assistant Professor of Medicine, Harvard Medical School). Michelle Lavin (WFH VWD & RBD Committee Chair), Baiba […]

Medical Plenary: Gene Therapy | Virtual Summit 2020 – Arabic

In this session from the WFH 2020 Virtual Summit, Steve Pipe and Luigi Naldini explore the promise of gene therapy and the broad-based multi-stakeholder preparation that is needed to deliver on this achievement. Steve Pipe explores that, although we currently stand on the threshold of this achievement, delivering on this promise will require broad-based multi-stakeholder […]

WFH Guidelines for the Management of Hemophilia | Virtual Summit 2020 – Arabic

In this session from the WFH 2020 Virtual Summit, Glenn Pierce, Alok Srivastava, Steven Pipe, Manuel Carcao, Margaret Ragni and Johnny Mahlangu present and discuss updates to the WFH Guidelines for the Management of Hemophilia. Discussion topics include hemostatic agents, prophylaxis, inhibitors, and treatment of specific hemorrhages. Click on the icon below to access more […]

Economic Benefits of Home Therapy – Arabic

Also Available In: Japanese Access to home treatment reduces the economic impact on healthcare systems and improves the quality of life for both the person with hemophilia and his family.

Benefits of Treating Hemophilia with Factor Concentrate – Arabic

Also Available In: Japanese Treating people with hemophilia with safe, regulated plasma-derived factor concentrate directly reduces the social and economic impact of this bleeding disorder on the patient as well as the amount of long-term support required from family, community, and government.

Economic Benefits of Basic Hemophilia Treatment & Care – Arabic

Also Available In: Japanese This fact sheet demonstrates the benefits of providing basic treatment and care to people with hemophilia. Adequate care includes access to a hemophilia treatment centre and to treatment products, and education for healthcare providers, patients, and families.